The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s non-alcoholic steatohepatitis treatment market report forecasts the non-alcoholic steatohepatitis treatment market size to grow to $6.87 Billion by 2027, with a CAGR (compound annual growth rate) of more than 38%.

Learn More On The Non-Alcoholic Steatohepatitis Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non-Alcoholic Steatohepatitis Treatment Market Size Forecast
The global non-alcoholic steatohepatitis treatment market is expected to grow from $1.36 billion in 2022 to $1.89 billion in 2023 at a compound annual growth rate (CAGR) of 38.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-alcoholic steatohepatitis treatment market size is expected to reach $6.87 billion in 2027 at a CAGR of 38.1%.

North America held the largest non-alcoholic steatohepatitis treatment market share.

Key Non-Alcoholic Steatohepatitis Treatment Market Driver ­– Increase In The Prevalence Of Insulin Resistance
For instance, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in November 2021, according to statistics published by gov.UK, a United Kingdom public sector information website, the rate of early death due to liver disease increased considerably in 2020 compared to 2019. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.

Request for A Sample Of The Global Non-Alcoholic Steatohepatitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Key Non-Alcoholic Steatohepatitis Treatment Market Trend – Developing The Non-Alcoholic Steatohepatitis Drug
Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as; ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Non-Alcoholic Steatohepatitis Treatment Market Segment
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Non-Alcoholic Steatohepatitis Treatment Market Major Players and Strategies
Major players in the non-alcoholic steatohepatitis treatment market are AstraZeneca Plc., Tobira Therapeutics Inc., Galmed Pharmaceuticals, Genfit SA, Zydus Cadila, Bristol Myers Squibb, Gilead Science, Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corporation, Inventiva Pharma, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals, and Gemphire Therapeutics.

In July 2022, Advanz Pharma, a UK-based pharma company, acquired Intercept Pharmaceuticals for an undisclosed amount. The acquisition includes the ex-US rights to commercialize the orphan drug Ocaliva® (obeticholic acid) for primary biliary cholangitis (PBC). Intercept Pharmaceuticals, Inc. is a US-based biopharmaceutical company focused on developing novel synthetic bile acid analogs to treat chronic liver diseases and non-alcoholic steatohepatitis disease.

The Non-Alcoholic Steatohepatitis Treatment Global Market Report 2023 covers regional data on non-alcoholic steatohepatitis treatment market size, non-alcoholic steatohepatitis treatment market trends and drivers, opportunities, strategies, and non-alcoholic steatohepatitis treatment market competitor analysis. The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.

View More Reports Related To The Non-Alcoholic Steatohepatitis Treatment Market –
Alcoholic – Beverages Global Market Report 2023
Non Alcoholic – Beverages Global Market Report 2023
Non-Alcoholic Beer Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: